BackEsperion Therapeutics Overview
Esperion Therapeutics Inc.

Esperion Therapeutics Target Price

Analysts' average 12-month price target for Esperion Therapeutics is $3.2.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.18

Average Target Price

$3.190.3% upside

4 analysts in the last 4 months

High: $3.28 | Low: $3.16

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-05-01Jefferies$3.283.1% upsideOpen
2026-05-01Piper Sandler$3.160.6% downsideOpen
2026-05-01H.C. Wainwright$3.160.6% downsideOpen
2026-05-01Cantor Fitzgerald$3.160.6% downsideOpen
2025-11-24Piper Sandler$9183% upsideOpen
2025-09-25Cantor FitzgeraldKristen Kluska$9183% upsideOpen
2024-12-17Cantor FitzgeraldKristen Kluska$8151.6% upsideOpen
2022-05-04NeedhamSerge Belanger$12277.4% upsideOpen
2021-05-04Wells FargoDerek Archila$20528.9% upsideOpen

Esperion Therapeutics (ESPR) FAQ

Esperion Therapeutics (ESPR) currently reports a target price of $3.2. Use the charts on this page to explore Esperion Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Esperion Therapeutics is $3.2, about 0.3% upside from the current share price of $3.18. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $3.2, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Esperion Therapeutics, and consider following ESPR for alerts when major investors trade the stock.

Esperion Therapeutics is classified in the Healthcare sector. On target price, it currently shows $3.2. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ESPR with unrelated industries.